Login to Your Account

Promethera Brings in $23M for Liver Stem Cell Therapy

By Cormac Sheridan
Staff Writer

Wednesday, April 4, 2012

Promethera Biosciences SA raised €17 million (US$22.7 million) in a Series B round last week to fund the first clinical trials of its allogeneic stem cell therapy for pediatric and adult liver disorders. It also received a further €6.6 million in loan financing from Belgium's Walloon region.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription